Dec 18, 2015
Media Statement
AbbVie and the Medicines Patent Pool (MPP) have completed a new licensing agreement to address future demands for HIV-1 treatment Lopinavir/Ritonavir (LPV/r) in South Africa and across Africa.  The agreement has been reached to help ensure sustainable, long-term supply of LPV/r in South Africa and the African continent.  LPV/r is a component of the most widely used HIV-1 treatment for second-line patients in the region. Our company is committed to providing treatment to people living with HIV and believes that Africa’s increased HIV testing efforts requires a strategy which is appropriate for Africa.  AbbVie has a longstanding and ongoing commitment to people living with HIV-1 worldwide. 

Read the announcement from the MPP here.
For further information please contact:
For Africa Media Inquiries:
Ahmed Negm
ahmed.negm@abbvie.com

For Global Media Inquiries:
Ilke Limoncu
ilke.limoncu@abbvie.com
 
<< Back